With a late Thursday nod from the FDA to reduce protein levels in the urine of patients with primary immunoglobulin A ...

Esteve CDMO, the contract development and manufacturing organization within Spanish specialty pharma Esteve, is overhauling ...

After disappointing Wall Street for most of 2026, Roche’s eye disease drug Vabysmo met analysts’ expectations for the first ...

Pfizer’s newest round of workforce cuts may be getting an early start.  | Local news reported Pfizer layoffs in Michigan and ...

The PMCPA has ruled that Otsuka Europe’s involvement with a sponsored symposium | The PMCPA has ruled that Otsuka Europe’s involvement with a sponsored symposium webpage breached 11 clauses of the U.K ...

The FDA rebuked Baxter in a lengthy warning letter that outlined a series of production violations that led to a trio of ...

This week, the companies announced wins across their late-stage Clarity-1 and Clarity-2 studies of once-daily brepocitinib in ...

Delaying the use of subcutaneous Parkinson’s disease treatments by one year increases annual medical costs by 59.1%, ...

Alcon—the eye-focused pharma spun out of Novartis—is handing over $550 million to buy out Neurotech Pharmaceuticals, its ...

Recruiting an industry veteran to steer the company through its darkest hour of growth pressures, CSL has hired GSK’s Deborah ...

In its own approval announcement on Oct. 20, the FDA hailed Hibsago as a “first-of-its-kind” treatment in chronic hepatitis B ...

As policies from the last two presidential administrations put heightened focus on drug affordability in the United States, a ...